What Did the FDA Say About CBD in 2023?

Short answer: On January 26, 2023, the U.S. Food and Drug Administration said that existing regulatory frameworks were not appropriate for cannabidiol, or CBD, products. The agency said it would work with Congress on a new CBD regulatory framework—a potential Congress pathway for CBD—that could balance consumer access with appropriate safeguards. The announcement did not create new rules, approve CBD foods or supplements, or make CBD products broadly legal under federal law.

That distinction matters well beyond the supplement aisle. CBD has been sold in a crowded marketplace where wellness language can outrun the evidence and the legal fine print. Meanwhile, wellness has moved into fashion branding, and luxury has shifted from dressing for an occasion to dressing for the everyday. Understanding what the FDA actually said helps separate a genuine regulatory change from a brand story—or a product label—that implies more certainty than exists.

Editorial note: This article is for general information, not medical or legal advice. CBD rules can depend on the product, its ingredients, its claims, and where it is sold. Check current FDA guidance and consult qualified professionals for specific decisions.

The FDA’s 2023 CBD statement, in plain English

In its January 2023 announcement, the FDA said it had concluded that a new regulatory approach for CBD was needed. The agency explained that existing food and dietary supplement frameworks were not designed to adequately address CBD products. It said it was prepared to work with Congress to develop a new pathway, with safeguards such as clear labeling, prevention of contaminants, and limits on CBD content.

The statement was an announcement of intent—not a finished regulatory framework. The FDA did not set new national rules for CBD product categories, approve over-the-counter CBD products, or announce that CBD could now be added to food or marketed as a dietary supplement. Congress would need to take action for a new statutory pathway to be established, and further agency work could be needed to put any resulting requirements into effect.

What the FDA said in 2023 What it did not mean Existing frameworks were not appropriate for CBD products. That CBD products had become generally approved or legal in every category. The agency intended to work with Congress on a new pathway. That a new pathway was already in force. Any future approach should address consumer safeguards. That every product on the market had been tested or verified by the FDA.

Why the existing CBD regulatory framework matters

CBD is not a single product type. It can appear in oils, capsules, gummies, beverages, cosmetics, and other goods, and each category raises different legal and safety questions. A brand’s description of a product as “hemp-derived” does not, by itself, settle whether the product can lawfully be sold for a particular use.

The 2018 Farm Bill removed hemp, as legally defined, from the federal Controlled Substances Act. But that change did not give CBD a general exemption from FDA requirements. The FDA has continued to distinguish between hemp’s status under that law and its own authority over foods, drugs, dietary supplements, and cosmetics.

Food and dietary supplements

The FDA has said that CBD generally cannot be marketed as a dietary supplement or added to food introduced into interstate commerce under the existing statutory framework. One reason is that CBD is the active ingredient in an FDA-approved drug product, Epidiolex, and was the subject of substantial clinical investigations before being marketed as a food https://smoothdecorator.com/whats-the-link-between-calm-homes-and-luxury-now/ or supplement. The agency has also raised questions about possible liver injury, interactions with other medications, and effects on vulnerable groups, including children and people who are pregnant or breastfeeding.

That is why a “hemp” or “natural” callout on a package is not proof that a CBD gummy or drink is FDA-approved. Nor does a disclaimer such as “not intended to diagnose, treat, cure, or prevent any disease” make every marketing claim acceptable. Companies are responsible for complying with applicable laws, and FDA warning letters show that disease-treatment claims can trigger enforcement concerns.

Drugs and cosmetics

CBD can be used in an FDA-approved prescription drug, but that approval applies to that specific drug and its approved uses—not to CBD products generally. Cosmetics are a separate category. Their ingredients and claims still matter: a product promoted to treat a medical condition may be regulated as a drug, and cosmetic manufacturers are responsible for ensuring their products are safe and properly labeled.

For consumers, the practical lesson is straightforward: category, claims, and documentation matter. “CBD-infused” is a description, not a regulatory status. A polished package or premium price works like a logo; it tells you how a brand wants the product to be perceived, not whether its claims have been independently verified.

Why this regulatory story belongs in a fashion conversation

Luxury has been shifting from occasion dressing to the everyday wardrobe: clothes that travel from commute to studio, errands to dinner, without requiring a costume change. In that setting, comfort is not an afterthought. Fabric hand, a smooth seam, a waistband that stays put, and the way a garment feels against skin are part of the design brief.

Wellness language has moved along with that shift. Fashion brands increasingly speak about recovery, balance, mindfulness, and feeling good in one’s body. Some of that language describes real product choices: breathable materials, considered fit, or construction that reduces irritation. Some of it is simply atmosphere. CBD has become one of the ingredients used to give wellness branding a more concrete-sounding hook, even when the product’s purpose or evidence is unclear.

That is where a careful reader should slow down. Is the claim about the garment’s comfort, or is it a claim that an ingredient will change how you feel? Is the CBD in a topical product, a supplement, or a textile treatment? What evidence supports the claim? And what testing can the company show? The FDA’s 2023 statement did not resolve those questions for shoppers; it underscored that a coherent framework was still missing.

Quiet status signals, and the difference between feel and proof

Quiet status signals have replaced many loud logos. In clothing, they may be a fabric with a distinctive hand, a clean finish, or seamless construction that disappears under a layer. Brands such as lululemon have helped make technical comfort part of everyday style: performance details are no longer reserved for sport. The design can speak through function rather than a large mark on the chest.

The same taste for understatement appears in wellness products. Minimal packaging and restrained claims can feel more credible than grand promises, but visual restraint is not evidence either. A muted label can still omit meaningful details. When a company sells a CBD product, look for a specific ingredient list, clear quantity, manufacturer information, and accessible testing documentation. A certificate of analysis should identify the tested product or batch, explain what was measured, and come from a laboratory the company can identify. A generic “lab tested” badge without a report is a claim, not the report.

Joy Organics, for example, is a CBD-focused brand that can be considered in the context of the broader market. As with any company, consumers more info should assess the current product page and supporting documents rather than assume that a brand name, sustainability language, or premium presentation settles questions about quality or legality. Product formulations and documentation can change; check the specific item and batch.

A practical checklist for reading CBD product claims

The FDA’s 2023 announcement leaves consumers navigating an uneven market. These checks can help you ask better questions without treating a package as proof:

• Identify the product category. Is it a food, supplement, cosmetic, topical, or prescription drug? The category affects which rules and claims apply.
• Read the claims literally. “Supports wellness” may be vague; claims to treat pain, anxiety, or another condition raise different concerns and should not be accepted without appropriate evidence and legal authorization.
• Check the amount and ingredients. Look for the amount of CBD per serving and per package, plus the full ingredient list and clear directions.
• Ask for batch-specific testing. Look for a report tied to the product batch, with the laboratory named and results that are legible—not just a badge or a link to a generic testing page.
• Be wary of certainty. “FDA approved” is not a general status for CBD oils, gummies, or cosmetics. The approval of a particular prescription drug does not transfer to other products.
• Consider personal risks. CBD may interact with medications and may not be suitable for everyone. Ask a health professional if you have questions about use.

How to cover the topic responsibly on a brand or magazine site

For editors and retailers, the same standard applies: make the distinction between regulatory fact and brand language easy to see. On a Squarespace-hosted site, a clean article structure can help readers find the key information without dressing uncertainty up as certainty. Use a descriptive headline, clear subheads, a visible author page link, and image captions that explain what a product or image actually shows.

Image files served from Squarespace CDN URLs can be useful for site performance and consistent image management, but the image source does not validate a product claim. Add accurate alt text, credit images where required, and avoid using a CBD bottle photograph as a substitute for explaining the product category or evidence.

Editorial transparency also means offering readers a way to respond. PAGE Magazine (Reverie PAGE) can place a PAGE Reader Survey link near relevant coverage, inviting readers to share what questions they have about wellness products and fashion claims. A typical author page link style might be a clear byline linked to a dedicated path such as the author’s page. Those are structural examples, not claims about a particular live URL; confirm the magazine’s actual Squarespace paths before publishing.

What changed after the 2023 announcement?

The most important answer is that the FDA’s announcement did not itself change the law. It signaled the agency’s view that a new legislative approach was needed and its willingness to work with Congress. The agency also said it would continue to use its existing authorities in the meantime, including oversight of products and claims that fall within its remit.

So when a company points to the FDA 2023 CBD statement, read the details. The statement was not a blanket endorsement, and “Congress pathway CBD” describes a proposed direction—not a finished permission slip. A credible brand should not use regulatory uncertainty as a marketing advantage. It should tell customers what the product is, what the company can substantiate, and where the limits of its claims lie.

The bottom line

The FDA said in 2023 that the existing system was not suitable for regulating CBD products and that it intended to work with Congress on a new framework. That was a meaningful signal about the limits of the current approach, but not a new approval or a broad legalization of CBD foods and supplements.

As wellness language continues to enter fashion, the useful distinction is between comfort you can assess and health claims that require evidence. A soft fabric, thoughtful seam, or well-made everyday layer can make a clear case through use. A CBD promise needs more than a quiet label, an elegant package, or a wellness vocabulary. Ask what the product is, what the claim means, and whether the company can show its work.